Tecarfarin - Cadrenal Therapeutics
Alternative Names: ATI-5000; ATI-5923Latest Information Update: 23 Sep 2024
At a glance
- Originator ARYx Therapeutics
- Developer Cadrenal Therapeutics; Espero BioPharma; Lee's Pharmaceutical
- Class Anticoagulants; Antithrombotics; Small molecules; Vascular disorder therapies
- Mechanism of Action Vitamin K epoxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Thromboembolism; Thrombosis
- Phase I Antiphospholipid syndrome
Most Recent Events
- 22 Aug 2024 Cadrenal Therapeutic plans type-B meeting with US FDA for clinical trial for Tecarfarin in Thromboembolism and Thrombosis (Prevention) in early September
- 22 Aug 2024 Cadrenal Therapeutic plans clinical trial for Thromboembolism and Thrombosis (Prevention)
- 07 Aug 2024 Cadrenal Therapeutics in collaboration with Abbott intends to initiate a pivotal study for Thromboembolism and Thrombosis (Prevention) in patients with recently implanted LVADs